Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial

OBJECTIVES: To determine the therapeutic equivalence and safety of once daily (OD) versus three times daily (TID) dosing of a total daily dose of 3 g Salofalk (mesalazine) granules in patients with active ulcerative colitis. DESIGN: A randomised, double-blind, double-dummy, parallel group, multicent...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kruis, W, Kiudelis, G, Rácz, I, Gorelov, I A, Pokrotnieks, J, Horynski, M, Batovsky, M, Kykal, J, Boehm, S, Greinwald, R, Mueller, R
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2009
Gaiak:
Inflammatory Bowel Disease
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3269751/
https://ncbi.nlm.nih.gov/pubmed/18832520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gut.2008.154302
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak